Anal Cancer begins in the anus and is typically curable, however its specific location, size, and nodal status are large factors in its treatment. Anal Cancer is highly uncommon as it only accounts for 4% of all cancers of the lower alimentary track. Of the approximate 4,000 cases reported each year in the United States, around 85% of victims are Caucasian with an average age of 62. Individuals who have many sexual partners and may be exposed to the human papillomavirus (HPV) have a higher chance of being diagnosed with anal cancer as HPV is highly associated with the onset of anal cancer. Recurrent Anal Cancer is a subtype of anal cancer that reoccurs or persists even after multiple treatments such as chemotherapy, surgery, and radiation therapy. Treatments for recurrent anal cancer include combined radiation and chemotherapy, and surgery as needed.
Anal Cancer Recurrent Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Anal Cancer Recurrent below!
For more information on how to use Laverne, please read the How to Guide.
We have 674 products for the study of Anal Cancer Recurrent that can be applied to Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.